Bluebird Bio Stock News

Both are making progress in a game-changing area.

Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.

SVB Leerink reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research report report published on Thursday, PriceTargets.com reports. Other analysts have also recently issued reports about the stock. Canaccord Genuity decreased their price objective on shares of bluebird bio from $20.00 to $15.00 and set a hold rating on the stock [] The post bluebird bio (NASDAQ:BLUE) Receives Hold Rating from SVB Leerink appeared first on ETF Daily News .

bluebird bio, Inc. (NASDAQ:BLUE) has received a consensus recommendation of Hold from the nineteen research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month []

In last trading session, bluebird bio Inc. (NASDAQ:BLUE) saw 2.7 million shares changing hands with its beta currently measuring 1.58. Companys recent per share price level of $11.12 trading at -$0.46 or -3.97% at ring of the bell on the day assigns it a market valuation of $687.77M. That closing price of BLUEs stock is Is bluebird bio Inc.s (NASDAQ:BLUE) Stock Expensive Or Cheap At $11.12? Read More »

BioLife: Poised For Growth

U.S. stock indexes finished lower Monday, as the fast-spreading omicron variant raised fresh questions about the outlook for the global economy.

The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.

Bluebird bio Inc said on Monday its gene therapy trial for sickle cell disease has been placed on partial hold for children while the company investigates the potential side-effect of persistent anemia in a patient.

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.

The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.

The FDA has placed a partial clinical hold on Bluebird bio Inc's (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) gene therapy program for sickle cell disease (SCD) for patients under the age

Bluebird Bio Inc. BLUE, +13.34% said Monday the Food and Drug Administration has placed a partial clinical hold on patients below the age of 18 in its lovo-cel sickle cell gene therapy program. The te

The FDA has accepted for priority review Buebird bio Inc's (NASDAQ: BLUE) marketing application for elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) in patients l